Pfizer announced it will supply atirmociclib for a study in collaboration with Olema Pharmaceuticals.
1 report, 1 independent
Updated Sep 2
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Pfizer announced it will supply atirmociclib for a study in collaboration with Olema Pharmaceuticals.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Pfizer
American multinational pharmaceutical and biotechnology corporation
-
Olema Pharmaceuticals (United States)
company in San Francisco, United States
Nothing else this week.
Related events
Coverage
Newest first; wire copies grouped- GlobeNewswireOlema Oncology Announces New Clinical Trial Agreement with Pfizer to Combine Palazestrant with Atirmociclib in ER+/HER2- Metastatic Breast Cancer Study to explore the palazestrant-atirmociclib combin